The Korea Times
Samsung Life Science Fund announced Thursday it will invest in Cartography Biosciences, a U.S. biotech company focused on tumor-specific antigen discovery. Samsung Life Science Fund is a venture investment fund jointly capitalized by Samsung C&T, Samsung Biologics and Samsung Bioepis, and managed by Samsung Venture Investment. The fund focuses on identifying global companies with innovative biotechnology to secure future growth engines. Cartography Biosciences holds a proprietary platform technology that combines single-cell genomic data with advanced bioinformatics to identify antigens. Through its in-house ATLAS and SUMMIT platforms, the company identifies tumor-specific antigens and antigen combinations, enabling the design of antibody therapies with greater targeting precision. Its lead pipeline candidate, CBI-1214, is a T-cell engager targeting colorectal cancer that entered Phase 1 clinical trials in early 2026 and is currently enrolling patients. Samsung said it plans to use the investment to expand a foundation for global collaboration with Cartography Biosciences, leveraging th
Go to News Site